Goldman Sachs has contributed a $20m extension to a Tasly Pharmaceuticals-backed round that achieved a first close at $35m in September.
China-based biotechnology company Ascletis secured a $20m extension to a series B round backed by drug developer Tasly Pharmaceuticals, from investment bank Goldman Sachs yesterday, to close the round at $55m.
Tasly co-led the round’s $35m first tranche in September 2015 with venture capital fund C-Bridge Capital and Pavilion Capital, a subsidiary of Singaporean state-owned fund Temasek.
Founded in 2011, Ascletis is developing treatments for infectious conditions such as HIV and cancer. The company has licensed one drug candidate…
